Ki-67 (MKI67)
EstablishedKi-67 is the core proliferation marker defining WHO neuroendocrine tumor grade, also widely used (if less formally endorsed) in breast cancer.
Ki-67 shows what fraction of tumor cells are actively dividing, and it's the single most important number used to grade neuroendocrine tumors, directly shaping treatment plans. It's also widely used in breast cancer, though interestingly, without full backing from official practice guidelines, and different labs don't always score it exactly the same way.
Ki-67 is a nuclear protein expressed exclusively in actively dividing cells, absent during the resting (G0) phase; immunohistochemical staining for Ki-67 is used as a proliferation index across multiple cancer types, most notably defining WHO grading of neuroendocrine tumors.
The WHO grading system for neuroendocrine tumors (connecting directly to the chromogranin A, gastrin, VIP, pancreatic polypeptide, neurotensin, and ProGRP entries elsewhere in this biomarker set) relies heavily on Ki-67: Grade 1 (<3%), Grade 2 (3-20%), and Grade 3 (>20%), directly determining treatment intensity and monitoring schedules.
Measured via immunohistochemistry (most commonly clone MIB-1) with manual or digital image analysis counting the percentage of positively stained tumor cells in the highest-labeling "hotspot" region; a well-documented limitation is significant inter-laboratory and inter-observer variability in scoring methodology, an active area of standardization efforts (WHO/ENETS guidelines, digital pathology tools).
In breast cancer, Ki-67 is widely used by clinicians as a prognostic marker despite lacking formal endorsement from major national oncology guidelines, reflecting a real gap between common practice and guideline-level evidence; in neuroendocrine tumors, Ki-67 grade directly guides how aggressively a tumor is followed and treated.
Significant inter-laboratory scoring variability remains an active, unresolved standardization challenge.
- NeuroEndocrine Cancer Australia. (2026). Role of Ki-67 Proliferation Index in NET Prognosis.
- OncLive. (2026). Ki-67 Is Poised to Advance as a Biomarker in Early-Stage Breast Cancer.